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Abstract 
We consider the analysis of clinical trials that involve randomization to an active treatment (T = 
1) or a control treatment (T = 0), when the active treatment is subject to all-or-nothing 
compliance. We compare three approaches to estimating treatment efficacy in this situation: as-
treated analysis, per-protocol analysis, and instrumental variable (IV) estimation, where the 
treatment effect is estimated using the randomization indicator as an instrumental variable. Both 
model-based and method-of-moment based IV estimators are considered. The assumptions 
underlying these estimators are assessed, standard errors and mean squared errors of the 
estimates are compared, and design implications of the three methods are examined. Extensions 
of the methods to include observed covariates are then discussed, emphasizing the contrasting 
role of covariates in these extensions. Methods are illustrated on data from the Women Take 
Pride study, an assessment of behavioral treatments for women with heart disease. 
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1. Introduction 
 Randomized clinical trials that compare treatments are straightforward to analyze when 
all individuals in the study take the assigned treatment, and outcomes are reported without 
missing data. The analysis and interpretation is complicated when individuals do not comply 
with their assigned treatments. The gold-standard analysis of such trials in drug approval 
processes is intention-to-treat (IT), where compliance information is ignored, and individuals are 
classified in treatment comparisons according to their assigned treatments, regardless of whether 
the treatment was taken. IT analysis preserves the benefits of randomized allocation of 
treatments, and it provides valid measures of the effect of treatment assignment, which is 
sometimes called treatment effectiveness. The analysis is less compelling for estimating the 
effect of treatment efficacy, which concerns the pharmacological or behavioral effectiveness of a 
treatment when it is in fact taken.  
Simple approaches to estimating treatment efficacy are as treated (AT) analysis, which 
compares average treatment effects with participants classified according the treatment actually 
received, and per-protocol (PP) analysis, which compares the average treatment effects for 
participants who comply with the assigned treatment. These analyses both classify participants 
according to received treatment, and hence are direct measures of treatment efficacy, but they are 
both subject to bias, in that participants who comply with a particular treatment may be a biased 
sample of participants randomized to that treatment. The selection bias may be reduced by 
adjustment for covariates, but it remains a concern. Thus current clinical tria l practice for 
estimating efficacy involves an unappealing choice between IT analysis, which is protected from 
bias by randomization but is really estimating effectiveness rather than efficacy, and PP and AT 
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analysis, which are directly attempting to measure efficacy but are subject to bias since the 
randomization is corrupted by treatment noncompliance.  
Recent literature has advocated another approach to estimating efficacy, based on treating 
the randomization as an instrumental variable (IV), in economic parlance. In simple terms the IV 
estimator corrects the IT estimator for noncompliance, based on certain assumptions about the 
outcomes for non-compliers under both treatments. This approach has the attraction of yielding a 
direct estimate of treatment efficacy, and is also protected from selection bias by the 
randomization. On the other hand, it does require certain assumptions to be valid, and it also 
yields estimators with potentially high variance, particularly if the treatment compliance rate is 
low.  Model-based versions of the IV estimator have been proposed that are potentially more 
efficient, although they make stronger distributional assumptions. 
The first objective of this paper is to provide a side-by-side comparison of the PP, AT 
and IV estimators of efficacy, which elucidates the assumptions made by the different methods 
and discusses their relative efficiencies. Previous papers that advocate the IV estimator and 
model-based enhancements essentially dismiss the PP and AT approaches because of their 
potential bias, but the assumptions under which these methods are valid are rarely explicitly 
articulated, and we think a direct side-by-side comparison of the methods is illuminating. We 
attempt to make the comparison as transparent and non-mathematical as possible, by focusing on 
the simplest non-trivial situation and avo iding unnecessarily algebraic formulations.  
A second objective is to elucidate and compare the role of covariates in improving the 
performance of the PP, AT and IV estimators. We show that covariates can reduce bias for PP 
and AT estimation but not for IV estimation, and can improve precision for all the methods. 
Finally we outline some extensions of these results to more general settings. 
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Our analysis provides an instructive non-technical introduction to some important ideas 
in causal inference, namely the definition of a causal effect of an active treatment as the 
difference in hypothetical outcomes under that treatment and a control treatment (Rubin 1974, 
1977, 1978), and the idea of principal stratification, where individuals are stratified according to 
the values of the post-treatment variable under both treatments, rather than simply under the 
treatment actually observed (Frangakis and Rubin, 2002). 
2. The Women Take PRIDE Study 
 Data from the “Women take PRIDE” (WTP) heart disease management study (Janevic et 
al., 2003) are used to illustrate our methods. In this study, participants are elder women with 
heart disease and the intervention is a self- regulatory process for identifying and resolving 
problems in managing their heart conditions (e.g., increasing physical activity). Two versions of 
the intervention were administered: a Group format, where 6-8 women study the educational 
material for 2-2.5 hours/week in a group setting; and a Self-Directed format, where each 
participant studies the same content on an individual basis at home after attending an in-person 
orientation session. The intervention program consists of 6 weekly classes for the Group format 
and 6 weekly units for the Self-Directed format. Compliance is defined as attendance of at least 
once Group class, or, equivalently, completion of at least one Self-Directed weekly unit. 
 This study adopted a doubly randomized preference trial (DRPT) (Long et al. 2006), with 
both a completely randomized arm (n=575), where participants were randomized to Group 
format, Self-Directed form and a control “usual care” format, and a choice arm (n-553) where 
participants were allowed to choose their treatment. One of the objectives in the WTP study is to 
assess efficacy of disease-management programs compared to the control format, accounting for 
noncompliance. The outcomes of interest include indicators of physical, psychological, and 
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functional health status, measured at baseline and months 4, 12, and 18. For more details on the 
WTP study, see Janevic et al., 2003.  
The purpose of this paper is to provide an in-depth comparison of the assumptions, 
properties and relationship of the as-treated (AT), per-protocol (PP) and instrumental variable 
(IV) estimators for treatment efficacy in trials involving an active treatment and a placebo. We 
hence restrict our attention to the randomized arm, and compare subjects assigned to Group 
format (T=1, n=190) with the control format (T=0, n=184). In particular, we choose the outcome 
“6 minute walk” at Month 12, which measures the distance in feet an individual can walk in 6 
minutes. Baseline 6-minute walk, and demographic characteristics at baseline, namely age and 
employment status, are chosen as covariates for methods involving covariate adjustment.  
3. The Problem  
We consider the analysis of clinical trials that involve randomization to an active 
treatment (T = 1) or a control treatment (T = 0), when the active treatment is subject to all-or-
nothing compliance (Baker 1997). It is assumed that compliance to the control treatment is 
perfect, so noncompliance is only an issue when assigned the active treatment. The population 
can then be divided into two groups: never-takers or non-compliers (C = 0), who take the control 
treatment whether they are assigned to the control or active treatment, and compliers who take 
the treatment they are assigned (C = 1). We call the variable C principal compliance, since it is a 
special case of principal stratification, where subjects are classified by the values of a post-
treatment variable (here compliance) under both treatments (Frangakis and Rubin 2002). Note 
that principal compliance is not the same as observed compliance, which depends only on 
whether a participant complied with the assigned treatment. Specifically, principal compliance 
equals observed compliance for cases in the treatment group, since by assumption all individuals 
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would comply with the control treatment. For cases in the control group observed compliance is 
always one, but principal compliance is unobserved, since we do not know if individuals would 
have complied if they had been assigned the active treatment. The key feature of principal 
compliance is that, unlike observed compliance, it is not affected by the treatment assigned, and 
hence can be used as a stratification variable in treatment comparisons, if the missing data 
problem can be solved.  
As discussed in Section 6, our analysis extends readily to the case where there is a third 
group, always-takers, who take the active treatment whether or not assigned to the control or 
active treatment. For the moment we assume there are no always takers, as would be the case if 
individuals assigned to the control treatment cannot obtain access to the active treatment. 
An intention-to-treat (IT) analysis in this setting computes and compares the average 
outcome in the treatment and control groups, ignoring information on compliance. The IT 
analysis is protected from selection bias by the randomization, and it measures treatment 
effectiveness, which is the effect of assigning the treatment without regard to whether or not the 
treatment is in fact taken.  However, the IT analysis arguably does not provide a satisfactory 
estimate of efficacy, that is, the effect of the treatment itself, since treatment non-compliers are 
counted as treated cases even though they never received the treatment. We focus here on other 
approaches that use compliance information to estimate treatment efficacy. 
 Two simple and widely-used approaches to treatment efficacy are as-treated analysis 
(AT), where individuals are classified according to the treatment they actually received; that is, 
treatment non-compliers are included in the placebo group; and per-protocol analysis (PP), 
where only individuals who comply with the assigned treatment are included in the treatment 
comparison; that is, treatment non-compliers are excluded from the analysis. As noted in the 
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introduction, both of these analyses are subject to selection bias; for example in the case of PP 
analysis, compliers to the control treatment (by assumption, the entire population) may differ 
systematically from compliers to the active treatment, so the populations being compared are not 
comparable. An alternative approach known as instrumental variable estimation (IV) has been 
suggested, namely the IT estimate (the difference in means for treatment and control ignoring 
compliance) divided by the proportion of compliers in the treatment group (Bloom 1984; 
Newcombe, 1988; Robins 1989; Sommer and Zeger 1991; Baker and Lindeman, 1994; Angrist, 
Imbens and Rubin, 1996, henceforth denoted as AIR). As shown in the next section, the IV 
estimator is not subject to the selection bias noted for the AT and PP estimates, although it does 
require assumptions to be valid.  
 Since AT, PP and IV are all estimates of treatment efficacy, it is important to define 
precisely what we mean by that term. Two strands of the literature can be distinguished. One 
focuses on the complier-average causal effect (CACE), which is the average treatment effect in 
the subpopulation of principal compliers, for which C = 1 (AIR). An alternative estimand is the 
average treatment effect (ATE), which is defined as the difference in mean outcome if all 
individuals had been assigned and complied with the treatment and the mean if all individuals 
had received the control treatment. The ATE requires that it is reasonable to consider the 
treatment outcome for non-compliers, in the counterfactual event that they had complied with the 
treatment.  It is somewhat controversial whether this counterfactual event is useful to 
contemplate, and arguably this varies according to context. For example, noncompliance to a 
behavioral treatment such as an exercise regime might plausibly be changed by increased 
motivation, as might occur if evidence that the treatment is successful becomes widely known. 
On the other hand, if noncompliance to a drug is the result of intolerable side-effects, then 
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compliance may require a reformulation of the drug to remove the side effects. Arguably this 
may change the properties of the drug, and estimation of the ATE is consequently more 
speculative.  
 The distinction between the CACE and the ATE is not a major issue in our simple 
setting, since in the absence of covariates, the ATE and CACE reduce to the same estimand 
under the assumption that the average outcome under the treatment is the same for compliers as 
for non-compliers if they had in fact complied. In situations where this assumption does not hold, 
the ATE and CACE differ, but additional information than that assumed here is needed to 
estimate the difference.  
In the case where covariate information is available, the usual additional assumption to 
identify the ATE is that the average outcome under the treatment is the same for compliers and 
non-compliers within strata defined by the covariates. The CACE and ATE are then the same 
within strata, but the overall CACE and overall ATE differ in how the stratum-specific estimates 
are weighted when combining over strata; specifically for the CACE the natural choice is to 
weight using the covariate distribution of compliers, whereas for the ATE the natural choice is to 
weight using the covariate distribution of compliers and non-compliers. This difference in 
weighting is only important if the covariates modify the effect of the treatment and are related to 
compliance, and we think it is likely to be minor in many applications. We focus on the CACE in 
the sequel, in order to avoid the need for assumptions about counterfactual conditions. 
In the next section we introduce notation that allows us to define the PP, AT and IV 
estimators explicitly, and clarify the assumptions under which they yield consistent estimates of 
treatment efficacy. In Section 5 we consider the precision of the three estimates, and implications 
for allocation of the sample between the treatment and control group. In Section 6 we consider 
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extensions of the methods to include observed covariates are then discussed, emphasizing the 
contrasting role of covariates. Finally in Section 7 we discuss briefly generalizations of the 
problem considered here and make some closing remarks. 
4. The AT, PP and IV Estimators and When they are Consistent for the CACE 
 Let R denote the indicator for the random treatment assignment, with value 1 if an 
individual is assigned to treatment and 0 if assigned to control. Note that in our notation R is the 
treatment randomized, and T is the treatment received, so for non-compliers assigned the active 
treatment  R = 1 but T = 0. Let C be the indicator for principal compliance, with value 1 for 
individuals who comply with the treatment if assigned, and 0 otherwise. We make the stable 
unit-treatment value assumption (SUTVA) (Rubin, 1978), which implies that compliance and 
outcomes for individuals are not affected by the assignments and outcomes of other individuals 
in the sample (AIR). Table 1A shows a classification of the population by R and C, assuming a 
proportion a  of the population is assigned to the population and a proportion b  are principal 
compliers. The entries reflect the fact that R and C are independent, which is justified under the 
assumption that treatments are randomly assigned. The proportions in square parentheses are 
unobserved for the sample, since the principal compliance status of individuals in the control 
group is unknown – we do not know whether they would have complied with the active 
treatment if assigned to that treatment. 
 We now introduce an outcome variable Y, and let rcm  denote the mean of Y for the 
subpopulation with R = r and C = c; let rcy  denote the corresponding sample mean, and rcn  the 
corresponding sample size. The population means are displayed in Table 1B, with square 
parentheses indicating quantities for which the corresponding sample estimates are not observed. 
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The observed sample counts and means are shown in Table 1C. The CACE is then the difference 
in complier means, 11 01d m m= - .  
If principal compliance were known for all individuals in the sample, a direct estimate of 
the CACE would be 11 01y y- . However, in practice the means in the four cells of Table 1B are 
not observed, and additional assumptions are needed to yield a CACE estimate.  
One possibility is to assume 
 NCEC: 00 01m m= , (1) 
which asserts that the mean outcome in the control group is the same for principal compliers and 
never-takers. We label this assumption “no compliance effect for controls” (NCEC). Condition 
(1) is implied by the following conditional independence assumption: 
 NCEC*: [ | 0]Y C RÙ = , (2) 
where the symbol Ù denotes independence. Under NCEC or NCEC*, it is natural to estimate 
both 00m  and 01m  by the marginal control mean 0y + , leading to the PP estimate of the CACE: 
 11 0ˆPP y yd += - , (3) 
which includes cases that take their assigned treatments. The problem with this estimator is that 
the NCEC assumption is generally considered questionable, since compliers and non-compliers 
may differ on various unobserved characteristics related to the outcome under the control 
treatment. NCEC can be weakened by adjusting for known covariates that characterize 
differences between compliers and never-takers, as discussed Section 5. 
 Note that participants in the subpopulation of never-takers (C = 0) are randomly assigned 
to treatment or control, and in both cases they receive the same (control) treatment. Thus it is 
often reasonable to assume the means in the first column of Table 1B are equal, that is: 
http://biostats.bepress.com/harvardbiostat/paper84
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 00 10ER: m m= . (4)   
This assumption is often called the exclusion restriction (ER) in the literature, a term that 
originates in the econometric literature (see e.g. AIR). The ER assumption is implied by the 
following conditional independence assumption: 
 ER*: [ | 0]Y R CÙ = . (5) 
ER or ER*, though often plausible, are assumptions, since the outcome may be affected by 
whether treatment or control is assigned even though the resulting treatment remains the same, 
particularly in trials of behavioral interventions. Under ER or ER*, it is natural to estimate both 
00m  and 10m  by 10y . The estimate of 01m  that yields the marginal mean 0y +  when averaged with 
10y  is  
 01 0 0 00 10 01ˆ ( ) /n y n y nm + += - , (6)  
but this cannot be computed since 00n  and 01n  are unobserved. However, the principal 
compliance rate for controls 01 0/n n +  can be estimated by the principal compliance rate for cases, 
11 1/n n + , since the underlying population rates are the same by randomization. Replacing 01 0/n n +  
by 11 1/n n +  in (6) yields 01 1 0 10 10 11ˆ ( ) /n y n y nm + += - , and the following IV estimate of the CACE: 
 11 01 1 0ˆ ˆˆ( ) ( ) /IV y y yd m b+ += - = - , (7) 
the intention to treat estimator divided by 11 1ˆ /n nb += , the compliance rate for cases. The 
estimator (7) is commonly termed the instrumental variable (IV) estimate, since it is a special 
case of IV estimation with the randomization indicator as the instrument.  
Suppose now we assume NCEC and ER simultaneously: 
 00 01 10NCEC + ER: m m m= = , (8) 
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or the corresponding conditional independence assumptions NCEC*+ER*. The natural estimate 
of the control mean is 0 0 0 10 10 0 10( )/( )y n y n y n n+ + += + + , pooling the data in the three cells that 
receive the control treatment T = 0. The resulting estimate of the CACE is AT estimate  
 11 0ˆAT y yd = - , (9) 
which classifies all cases according to the treatment they received.  
To summarize, the NCEC assumption leads to ˆPPd , the ER assumption leads to ˆIVd  and 
the NCEC and ER assumptions combined lead to ˆATd . The choice between the estimators rests 
largely on the perceived validity of their underlying assumptions, although the precision of the 
estimates may also play a role.  
5. The Precision of the Alternative Estimators, and Design Implications  
5.1. Comparison of the AT, PP and IV Estimators  
For simplicity, we assume that the within-cell variance of Y in each of the cells in Table 1 
is 2s ; also since the ER assumption is often plausible, we compare biases and variances of the 
estimates under that assumption. Under these conditions, the large-sample biases of the ER, PP 
and AT estimates are 
 ˆ( ) 0IVB d = , (10) 
 ˆ( ) (1 )PPB d b s= - D , (11) 
 
1ˆ( )
1AT
B
b
d s
ab
-
= D
-
, (12) 
where 01 00( ) /m m sD = - , which is zero under the NCEC assumption. The large sample variances 
of the three estimators are  
 ( )
2
2
2
ˆ( ) 1 (1 )
(1 )IV
Var
n
s
d b b
a a b
= + - D
-
, (13) 
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 ( )
2
2 2ˆ( ) 1 (1 )
(1 )PP
Var
n
s
d ab a ab b
a a b
= + - + - D
-
, (14) 
 ( )
2 2
2
4
1 1 (1 ) (1 )ˆ( ) 1 2
1 (1 )AT
Var
n
s a b b
d ab ab
ab ab ab
æ ö- - D
= + + - +ç ÷- -è ø
, (15) 
. It can be shown with some algebra that 2 2 2IV PP ATs s s³ ³ .  
IV is markedly less efficient than PP and AT for small values of b . This is illustrated in 
Figure 1, which plots the asymptotic relative efficiencies ˆ ˆ( ) / ( )PP IVVar Vard d  and 
ˆ ˆ( ) / ( )AT IVVar Vard d  of IV compared to PP and AT against b , when 00 10 0m m= = ,  11 2m = , 
2 1s = , 0.5a = . Figures 2 and 3 show the mean squared error (MSE = 2 ˆ ˆ( ) ( )B Vard d+ ) of the 
three estimators for various choices of ,a b  and D , which are measured in units of n2s . If we 
assume both ER and NCEC, that is, 0=D , ˆATd  is preferred to ˆIVd . If we assume ER but do not 
assume NCEC, that is, 0¹D , ˆATd  might still be preferred to ˆIVd , if the bias is small and 
compensated by a large reduction in variance. (For given  bias, bias increasingly dominates 
variance as the sample size increases, so in large samples ˆIVd  is preferred to both ˆATd  and ˆPPd .) 
If one of either NCEC or ER is assumed true, the other assumption can be tested 
empirically by comparing 10 0y y +-  with zero; since IV and AT both assume ER, one might 
increase the efficiency of the CACE estimate by choosing AT over IV if this test is not rejected, 
or the difference 10 0y y +-  is “small”. This approach has most appeal when the compliance rate is 
low, since in this case ˆIVd  has substantially higher variance and the power of the test may be 
reasonable; when compliance is high the power of the test is very modest. An indirect approach 
to checking the ER assumption using covariates is discussed in Section 6 below. 
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What fraction a  of cases should be assigned to the treatment group for optimal 
efficiency? Differentiating (13) with respect to a , the variance of the IV estimate is minimized 
when 0.5a = , that is, an equal allocation of treated and control cases. One might think that 
given noncompliance, more cases should be assigned to the treatment group, but an equal 
allocation is optimal for the IV estimator under our variance assumptions. On the other hand, the 
variance of the per-protocol  estimate is minimized when ( )21/ 1 (1 (1 )PPa a b b b= = + + D - . 
When 0D = , ( )1/ 1PPa b= + , which does assign more cases to the treatment group when there 
is noncompliance. 
5.2 CACE Estimates for the Women Take Pride Study 
We illustrate the AP, PP and IV estimates with data from the Women Take Pride (WTP) 
study. As discussed in Section 2, we restrict attention to randomized subjects, and compare 
women assigned to Group behavioral intervention (R =1) with the Control “usual care” treatment 
(R =0).  
Table 2 shows the observed counts and means for the outcome “6 minute walk” taken at 
month 12, measuring the distance in feet an individual can walk in 6 minutes. These analyses 
exclude 69 of the 190 cases in the intervention group and 62 cases in the control group who drop 
out before month 12. For the current analysis we assume that drop out is random within each 
treatment group – the analysis in Section 7.2 relaxes this assumption by allowing dependence of 
the dropout on baseline covariates. In the treatment group ˆ 105/121b = =86% complied with 
treatment, where compliance is defined here as completion of at least one of the treatment 
modules. Table 2 also shows the estimated cell means from the (a) PP, (b) IV and (c) AT 
methods; the estimated means in italics are equated because of the model assumptions. For 
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example, the mean for compliers in the control group equals the mean for compliers in the 
treatment group by ER, and is estimated to be 694.12; the mean for compliers in the control 
group equals the mean for non-compliers in the control group by NCEC and is estimated to be 
748.90. The last row of the lower panel of Table 2 shows the corresponding estimates of the 
CACE, and associated standard errors, computed using Eqs. (13)-(15). Note that the estimates of 
the CACE from the three methods are somewhat different, and the PP and AT estimates are 
statistically significant at the 0.05 alpha level. The standard errors are ordered as described 
above, with relative small differences since the compliance rate is quite high in this application. 
The t-test for the combined NCEC + ER assumptions compares the mean for controls (748.90) 
with the mean for treatment non-compliers (694.12), statistically not significant even though the 
difference in means is quite substantial. This illustrates the low power of the test when the 
compliance rate is high.  
6. Model-Based Estimation 
We have noted that the potentially high variance of the IV estimator when the compliance 
rate is low. The precision of ˆIVd  can be improved by seeking a more efficient estimator. 
Technically all the estimators considered so far can be viewed as method-of-moment estimators 
under the various assumptions. Another approach to inference is maximum likelihood (ML) 
estimation based on a model for the joint distribution of Y, R and C. In particular, suppose Y 
given R, C is assumed normal with mean rcm  and variance 
2s . The loglikelihood of the 
observed data, assuming independent observations, is: 
( )
( ) ( )
2 2 2 2
1,: 1
2 2 2 2
01 00: 0
{ }, , | 0.5 log 0.5( ) /
log exp 0.5( ) / (1 )exp 0.5( ) / ,
ii
i
rc i ci r
i i i ii r
data n y
y y
m b s s m s
p m s p m s
=
=
= - - -
é ù+ - - + - - -ë û
å
å
l
 
Hosted by The Berkeley Electronic Press
 16 
where ip  is the compliance rate for subject i, and is assumed equal to b  with no covariates.  
Without constraints on { }crm , the means in this loglikelihood are not identified, but they are 
identified under the ER and/or NCEC assumptions. It is easily shown that ˆPPd  is ML for this 
model under the NCEC assumption (1), and ˆATd  is ML under the NCEC and ER assumptions 
(8). However ˆIVd  is not the ML estimate under the ER assumption (4). The ML estimate (say 
ˆ
MLERd ) does not have an explicit form, but is quite easily computed using the EM algorithm, 
treating the compliance indicators for the controls as missing data (AIR). 
The estimate ˆMLERd  is more efficient than ˆIVd  (Imbens and Rubin 1996), but makes 
stronger distributional assumptions; in particular, we conjecture that it is sensitive to violations 
of the assumption of a constant variance for compliers and non-compliers when R =0. While 
ˆ
MLERd  and ˆIVd  differ under the normal model, the ML estimate equals ˆIVd  for binary outcomes Y 
with a Bernoulli distribution, providing the resulting means in Table 1B, which are estimated 
probabilities for a binary Y, all lie between zero and one (Baker and Lindeman 1994).  
7. Methods That Include Covariate Information 
7.1. CACE Estimation with Covariates. 
 We now consider how covariates X measured for compliers and non-compliers can be 
used to improve the performance of the AT, PP and IV estimates. Related questions are the 
properties of a good covariate, and approaches to dimension reduction when a large number of 
covariates are available.  
For AT and PP, the covariates can be adjusted by a regression model of Y on X and a 
dummy variable T for the received treatment. All cases are included for AT analyses, and non-
compliers assigned the treatment are excluded for PP analysis. As in covariate adjustments in 
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observational settings, inclusion of X can reduce selection bias from noncompliance and increase 
precision. Concerning bias, a correctly-specified regression adjustment with covariates X 
weakens NCEC* in (2) to 
 NCEC*( ): [ | , 0]X Y C X RÙ = , (16) 
that is, to an assumption that there is no compliance effect for controls within strata defined by X. 
Covariates that are predictive of the outcome can also increase precision by reducing the residual 
variance 2s  of the regression of Y on X and T.  
A strategy for robust modeling when there are a number of covariates is to stratify on a 
coarsened function ( )c X  of the covariates X. To limit bias, a function is sought such that if (16) 
is true, then it remains valid with X replaced by ( )c X . A standard application of the propensity 
score theory of Rosenbaum and Rubin (1983) implies that the coarsest function ( )c X  with this 
property is the propensity to comply, ( ) ( 1 | )p X p C X= = . This score can be estimated by 
regressing the compliance indicator C on the covariates using the cases assigned to treatment; 
control cases are excluded since C is not known for them. Note that the same propensity score 
applies for both AT and PP, because the NCEC assumption is shared by both methods. AT also 
requires the ER assumption, but that is not addressed by the propensity adjustment. 
Covariates do not play a role in bias reduction for the IV method. To see this, suppose 
ER* is assumed conditional on X, that is  
 ER*( ): [ | , 0]X Y R X CÙ = . 
Then in terms of densities, 
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( | 1, 0) ( | , 1, 0) ( | 1, 0)
( | , 0, 0) ( | 1, 0)
( | , 0, 0) ( | 0, 0)
( | 0, 0),
p Y R C p Y X R C p X R C dX
p Y X R C p X R C dX
p Y X R C p X R C dX
p Y R C
= = = = = = =
= = = = =
= = = = =
= = =
ò
ò
ò
 
where the first and last equalities are by definition, the second is implied by ER*(X), and the 
third equality is true by the randomization of treatments. Thus ER*(X) implies ER*, so the latter 
is not weakened by conditioning on X, and the covariates do not play a role in bias reduction.  
Covariates can be used to increase the precision of ˆIVd , however. We first consider the 
modification of ˆIVd  for a single categorical X with J categories. Denote the IV estimator within 
the stratum X j=  as , 1 0ˆ ˆ( ) /IV j j j jy yd b+ += - , with the subscript j  denoting stratum. Let jp  be 
the proportion of cases in stratum j, estimated from the pooled sample. Then 
1
ˆ ˆ/
J
j j k kk
p pb b
=å  
estimates the proportion of compliers in stratum j. Weighting ,ˆIV jd  by this proportion and 
summing over strata yields the stratified IV estimator  
 | 1 01 1
ˆ ˆ( ) /
J J
I V X j j j j jj j
p y y pd b+ += == -å å . (17) 
The numerator of |I V Xy  is a stratified form of the IT estimator, and its precision is improved by 
stratifying on covariates that are predictive of the outcome. The denominator of |I V Xy  is a 
stratified estimator of the overall compliance rate, and its precision is improved by stratifying on 
the covariates that are predictive of compliance. We conjecture that the former of these two 
components has the greater potential for variance reduction. A natural generalization of |I V Xy  for 
a set of categorical and/or continuous X’s is  
 | 1 0ˆ ˆˆ ˆ( ) /I V X i i ii iy yd b= -å å , (18) 
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where the summation is over all individuals i in the sample; ˆriy  is the predicted outcome for unit 
i if randomized to treatment r, computed from a regression of Y on X and R; and ˆib  is the 
predicted true compliance for unit i, computed from a regression of C on X estimated from the 
cases assigned to treatment. The latter should be of a form appropriate for a binary outcome, for 
example logistic or probit regression. We are not aware of discussions of (17) or (18) in the 
compliance literature. 
An alternative to (17) or (18) is to compute ML or Bayes estimates of the CACE given 
covariates X, using a full model for the distribution of Y and C, given R and X, and treating the 
compliance indicators in the control group as missing covariates (Imbens and Rubin, 1997a; 
Little and Yau 1998). The model can be specified in terms of a compliance model for C given R 
and X indexed by parameters Cq , and an outcome model for Y given C, R and X indexed by 
parameters Yq .  The loglikelihood takes the form 
( ) ( ) ( )( )
( )( )
obs
1
0
( , | , , ; , )
log ( | , , ; ) log ( ; ) (1 )log 1 ( ;
log ( ; ) ( | , , 1; ) 1 ( ; ) ( | , , 0);
i i
i
i i i i
i
Y C Y C
i i Y i Y i i C C i i Ci C
R
i C C i i Y i Y i C C i i Y i Y
R
Y C R X X
f Y R X C C X C X
X f Y R X C X f Y R X C
q q
q p q p q
p q q p q q
=
=
=
+ + - -
é ù+ = + - =ë û
å
å
l
  (19) 
In these models, the compliance model should exclude the main effect of R and interactions 
including R, because of the assumption of randomization of treatments. The outcome model 
should exclude effects of the form RU, where U is the identity or a set of some or all the 
covariates, because these effects concern the effects of compliance for controls, which are 
assumed zero under ER. The modeling approach yields gains of efficiency over the IV approach 
(Imbens and Rubin 1997a, 1997b), but may be more vulnerable to model misspecification; more 
simulations comparing the methods would be of interest. 
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We noted in Section 4 that the data do not provide evidence of the validity of ER or 
NCEC. With covariates, the same comment applies within strata defined by the covariates. 
However, if the covariates are good predictors of compliance, the relationship between outcome 
and predicted compliance can be assessed in the control group, and lack of evidence of a 
relationship might be construed as indirect evidence in favor of the NCEC assumption. 
Specifically, transform the covariates X into the propensity score ˆ ( )p X  and covariates Z 
orthogonal to ˆ ( )p X , and regress Y  on ˆ ( )p X  and Z in the control group. If the coefficient of 
ˆ ( )p X  in this regression is small, this provides some justification for the NCEC assumption, 
suggesting that PP or AT analysis may be reasonable options. On the other hand if the regression 
coefficient of ˆ ( )p X  is large, estimates like ˆIVd  or ˆMLERd  that do not require the NCEC 
assumption may be preferable. 
7.2 Women Take Pride  Data Analysis with Covariates 
We now extend our analyses in Section 5.2 to include adjustment for baseline covariates. 
We considered, in addition to 6-minute walk at baseline,  the covariates previously included in 
Janevic, et al. ( 2003), including age, employment and Symptom Impact Profile (SIP) physical 
score, which measures a subject’s physical functioning. The ML estimate of the CACE for the 
data without adjusting for covariates is ˆ 109.78MLERd = , close to the IV estimate of ˆ 108.76IVd =  
in Table 2. It has a slightly lower standard error (61.28 vs. 65.53). Table 3 shows the results of 
fitting a model of form (19) to the data from the WTP study. Block (1) shows the coefficients for 
the outcome model, with the CACE being the Compliance*Treatment interaction. Block (2) 
shows coefficients from the compliance model. The covariate-adjusted the ML estimate of the 
CACE from this model is 97.20 with a reduced standard error, namely 43.73, indicating some 
improvement in precision from adjusting for the covariates. In addition, women with higher 
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baseline measure tend to have higher 6-min walk measure at month 12, and older women tend to 
have lower 6-min walk measure at month 12. Table 4 summarizes the IV, MLN-ER, PP and AT 
estimates both with and without covariate adjustments. PP and AT estimates with covariate 
adjustments are obtained using linear regression adjusting for age, baseline 6-minute walk 
measurement, and employment status. Table 4 shows that covariate adjustment generally 
improves precision and reduces differences between the methods. The large gain in efficiency 
may be due to the significant effects of age and baseline measurements on the outcome of 
interest. The results suggest that compliers performed better under treatment rather than under 
control with respect to this outcome.   
8. Discussion.   
 We have compared a variety of methods for estimating efficacy in randomized trials for a 
control and active treatment, when there is all-or-nothing compliance in the treatment arm. This 
work applies directly to two active treatments A and B, when compliance is perfect for treatment 
A, and noncompliance to treatment B means taking treatment A. In practice, the choice of 
methods depends on various factors, effect sizes relative to between-subject variability of the 
outcome measure, sample size and differences in characteristics of compliers and non-compliers. 
The choice also depends on the plausibility of the different modeling assumptions and the trade-
off between efficiency and robustness. If NCEC or NCEC+ER given a set of covariates can be 
believed, and regressions on the covariates are correctly specified, then AT can be dramatically 
more efficient than IV. On the other hand, the IV estimate of the CACE under ER is robust 
against misspecification of our regression model or false belief in NCEC. Thus, it may be wise to 
compute and compare all the estimates to assess sensitivity of answers to the choice of method.  
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Many generalizations and extensions of these methods are possible. A relatively 
straightforward generalization is to add to the never-takers (C =0) and compliers (C =1) a 
subpopulation of always-takers (say C = 2), who obtain the active treatment whether assigned to 
treatment or control. This adds an additional column to Table 1. The CACE is still defined as the 
treatment effect in the subpopulation of compliers, the middle column of the tables, and a second 
restriction on the means is required to identify the parameters. The PP estimate assumes 
00 01m m=  (NCEC, as before) and also 11 12m m= , that is, the mean outcome under treatment is the 
same for compliers and always takers. The ER assumption in IT analysis yields two restrictions, 
00 10m m=  (as before) and 02 12m m= , that is, the treatment mean outcome for always-takers is the 
same regardless of the treatment assigned). The AT analysis assumes 00 01 10m m m= =  and 
11 12 02m m m= = , leading to pooling the means in the (00, 01, 10) and (11,12, 02) cells. The 
propensity to comply discussed in Section 3 is replaced by two propensities, 
Pr( 1| , 1, 1 or 0)C X R C= = =   and Pr( 1| , 0, 1 or 2)C X R C= = = .  An interesting new possibility 
is hybrid models that mix the NCEC and ER assumptions. For example one might assume 
00 01m m=  (NCEC) and 20 21m m=  (ER for always-takers only).  
A further extension is to allow the possibility of “defiers” who take the opposite of the 
treatment assigned (AIR). However this group requires additional assumptions to identify the 
parameters, and since defiance is incompatible with a consistent preference for one or other of 
the treatments, the assumption of “no defiers” is commonly made in practice.  
Other extensions that require more restrictions to identify the parameters include the case 
where partial compliance is modeled (Goetghebeur & Molenberghs 1996), or there are more than 
two treatments, such as two active treatments and a control treatment that is assumed to apply to 
non-compliers. CACE estimation in trials involving a control group and more than one treatment 
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groups is more complicated, and consists of more principal compliance categories and involves 
more complicated identifiability assumptions. The results will be reported elsewhere. 
Another extension is to consider joint models for noncompliance and missing data – for 
simplicity we confined our analyses of 12 month WTP data to completers. For some approaches 
to this issue see Frangakis and Rubin (1999) and Peng, Little and Raghunathan (2004). 
 
Acknowledgements. This research was supported by grant R01CA76404 from the National 
Cancer Institute. We thank Noreen Clark for kindly providing the data from the Women Take 
Pride Study that illustrate the methods. 
References 
Angrist, J.D., Imbens, G.W., & Rubin, D.B. (1996). Identification of causal effects using 
instrumental variables (with discussion and rejoinder). Journal of the American Statistical 
Association, 91, 444-472. 
Baker S. G. (1997). Compliance, all-or-none. In Kotz S, Read CR, Banks DL (eds.).The 
Encyclopedia of Statistical Science, Update Volume 1, 134-138. New York: John Wiley and 
Sons. 
Baker, S.G., & Lindeman, K.S. (1994). The paired availability design: a proposal for evaluating 
epidural analgesia during labor. Statistics in Medicine, 13: 2269-2278. 
Bloom, H.S. (1984). Accounting for no-shows in experimental evaluation designs. Evaluation 
Reviews, 8: 225-246. 
Frangakis, C. E. and Rubin, D. B. (1999). Addressing complications of intent-to-treat analysis in 
the combined presence of all-or-none treatment-noncompliance and subsequent missing 
outcomes. Biometrika, 86, 365-379.  
Hosted by The Berkeley Electronic Press
 24 
Frangakis, C.E. and Rubin, D.B. (2002). Principle stratification in causal inference. Biometrics, 
58, 21-29. 
Goetghebeur, E., & Molenberghs, G. (1996). Causal inference in a placebo-controlled clinical 
trial with binary outcome and ordered compliance. Journal of the American Statistical 
Association, 91: 928-934 
Imbens, G.W., & Rubin, D.B. (1997a). Estimating outcome distributions for compliers in 
instrumental variables models. Review of Economic Studies, 64: 555-574. 
Imbens, G.W., Rubin, D.B. (1997b). Bayesian inference for causal effects in randomized 
experiments with noncompliance. Annals of Statistics, 25: 305-327. 
Janevic, M.R., Janz, N.K., Dodge, J.A., Lin, X., Pan, W., Sinco, B.R., and Clark, N.M. (2003). 
The role of choice in health education intervention trials: a review and case study. Social Science 
and Medicine, 56, 7:1581-1594. 
Little, R.J.A. and Yau, L. (1998). Statistical techniques for analyzing data from prevention trials: 
treatment of No-Shows using Rubin's causal model. Psychological Methods, 3, 2, 147-159. 
Long, Q., Little, R. J. and Lin, X. (2006) Causal inference in hybrid intervention trials involving 
treatment choice. Journal of the American Statistical Association, in press. 
Newcombe, R.G. (1988).  Explanatory and pragmatic estimates of the treatment effect when 
deviations from allocated treatment occur. Statistics in Medicine, 7: 1179-1186. 
Peng, Y., Little, R.J. and Raghunathan, T. (2004). An extended general location model for causal 
inferences from data subject to non-compliance and missing values.  Biometrics, 60, 598-608. 
Robins, J.M. (1989). The control of confounding by intermediate variables. Statistics in 
Medicine, 8:  679-701. 
http://biostats.bepress.com/harvardbiostat/paper84
 25 
Rosenbaum, P., & Rubin, D.B. (1983). The central role of the propensity score in observational 
studies for causal effects. Biometrika, 70: 41-55. 
Rubin, D.B. (1974). Estimating causal effects of treatments in randomized and non-randomized 
studies. Journal of Educational Psychology, 66: 688-701. 
Rubin, D.B. (1977). Assignment to a treatment group on the basis of a covariate. Journal of 
Educational Statistics, 2: 1-26. 
Rubin, D.B. (1978). Bayesian inference for causal effects: the role of randomization, the annals 
of statistics, 6: 34-58. 
Sommer, A., & Zeger, S. (1991). On estimating efficacy from clinical trials. Statistics in 
Medicine, 10: 45-52. 
Hosted by The Berkeley Electronic Press
 26 
Table 1. Classifications by Treatment and Principle Compliance: (A) Population 
Proportions; (B) Population Mean Outcomes; (C) Observed Means (Sample Counts).  
 
A 
  Compliance C  
  0 1 ALL 
0 [ 1 )(1 )]a b( - -  [(1 ) ]a b-  1 a-  Randomized 
Treatment R 1 (1 )a b-  ab  a  
 ALL [1 ]b-  [ ]b   
 
[] = not observed 
B  
  Compliance C  
  0 1  
0 
00[ ]m  01[ ]m  0m +  Randomized 
Treatment R 1 
10m  11m  1m +  
  
0[ ]m+  1[ ]m+   
 
[] = not directly estimable without assumptions 
C.  
  Compliance C  
  0 1  
0 ? ? 
0 0( )y n+ +  Randomized 
Treatment R 1 
10 10( )y n  11 11( )y n  1 1( )y n+ +  
  ? ?  
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Table 2. Women Take Pride Study: (A) Sample Means (Sample sizes) for Outcome 6 
Minute Walk in Control and Group Treatment Subgroups, and (B) Predicted Means under 
PP, IV and AT Models. 
 
A 
 
  Compliance C  
  0 1  
0 ? ? 748.90 (122) Randomized 
Treatment R 1 694.12 (16) 866.01 (105) 843.28 (121) 
 
B 
Treatment R IV PP AT 
 Compliance 
0               1 
Compliance 
0               1 
Compliance 
0               1 
0 694.12        757.25 748.90        748.90        742.55        742.55        
1 694.12        866.01 694.12        866.01 742.55        866.01 
CACE 
(SE) 
108.76 
(65.53) 
  
117.11 
(58.97) 
 
123.45 
(57.37) 
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Table 3. Women Take Pride Study: ML estimates of Regression Coefficients of Models for 
the Outcome 6-Min Walk and Compliance with Covariates 
 
 
Parameter Estimate (B) SE(B) P-Value 
Outcome Model (1) 
Intercept 707.97 278.89 < 0.001 
Age -6.763 3.404 0.032 
 
Baseline 6-min Walk 0.707 0.048 < 0.001 
Employment 28.71 55.18 0.59 
Treatment Compliance -29.72 84.87 0.83 
Compliance *Treatment 97.20 43.73 0.043 
 
Compliance Model (2) 
Intercept 2.259 0.497 < 0.001 
Employment -0.464 
 
0.792  0.526 
 
Baseline SIP Physical -0.040 0.041 0.282 
 
 
 
Table 4. Women Take Pride Study: IV, MLN-ER, PP and AT estimates for the Outcome 6-
Min Walk, with and without covariate adjustment 
 
Covariates  IV MLN-ER PP AT 
Unadjusted Estimate 
SE 
108.76 
65.53 
 
109.78 
61.28 
117.11 
58.97 
 
123.45 
57.37 
 
Adjusted Estimate 
SE 
100.05* 
44.25* 
97.20 
43.73 
95.58 
40.30 
90.13 
38.74 
 
* Estimate is computed using formula (18) and its SE is computed using the bootstrap 
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Figure 1. Asymptotic Relative Efficiency of IV compared to PP and AT. 
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Figure 2. MSE of Estimates for varying population proportions in the treatment arm, a , 
when compliance rate , b =0.751, n=575 and treatment effect size Dn =0,5,10 clockwise 
for three graphs, respectively. 
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Figure 3. MSE of Estimates for varying compliance rate, b , when the population 
proportion in the treatment arm a =0.522, n=575 and treatment effect size Dn =0,5,10 
clockwise for three graphs, respectively. 
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Appendix: Large sample variances of IV, PP and AT 
All the estimates are of the form 10 11 0 ˆ( , , , )g y y y b+ , where 10 11 0 ˆ( , , , )y y y b+  are asymptotically 
independent with variances  
2
10
2
11
2 2
0
( ) ,
(1 )
( ) ,
(1 (1 ))
( ) ,
(1 )
(1 )ˆ( )
Var y
n
Var y
n
Var y
n
Var
n
s
a b
s
ab
s b b
a
b b
b
a
+
=
-
=
+ D -
=
-
-
=
 
Hence 
2 22 2
10 11 0
10 11 0
ˆ( ) ( ) ( ) ( ) ( )
g g g g
Var g Var y Var y Var y Var
y y y
b
b++
æ ö æ öæ ö æ ö¶ ¶ ¶ ¶
= + + +ç ÷ ç ÷ç ÷ ç ÷¶ ¶ ¶ ¶è øè øè ø è ø
 
(A) 11 10 0ˆ ˆ ˆ ˆ(1 ) / /IV y y yd b b b+= + - -  
1 1 10 0
2 2
10 11 0
ˆ
ˆ ˆ1, 1, , ˆ ˆ ˆ
g g g g
y y y
m m b s
b b
b b b
- - +
+
æ öæ ö æ öæ ö¶ ¶ ¶ ¶ - D
= - = = - = =ç ÷ç ÷ ç ÷ç ÷¶ ¶ ¶ ¶è øè ø è ø è ø
 
So [ ] [ ]
2 2 2 2 2
2 2 2
2 2 2
2
2
2
2
(1 ) 1 1 1 (1 ) (1 )ˆ( )
(1 ) (1 )
(1 )
(1 )(1 ) (1 ) (1 )
(1 ) (1 )
1 (1 )
(1 )
IVVar n
n n
n
s b b b b b
d
b a b ab b a b a
s s b
b a b a a a a
b a a ba a
s
b b
b a a
é ù- + D - D -
= + + +ê ú- -ë û
D -
= - - + - + + + -
- -
é ù= + D -ë û-
 
(B) 11 0ˆPP y yd += -  
11 0
1, 1
g g
y y +
æ öæ ö¶ ¶
= = -ç ÷ç ÷¶ ¶è ø è ø
 So 
2 21 1 (1 )ˆ( )
(1 )PP
Var
n
s b b
d
ab a
é ù+ D -
= +ê ú-ë û
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(C) 0 10 10 011 11 0
ˆ ˆ(1 ) (1 ) (1 )( )ˆ
ˆ ˆ1 1
AT
y y y y
y y y
a a b a b
d
ab ab
+ +
+
- + - - -
= - = - +
- -
 
2
10 11 0
ˆ(1 ) 1 (1 )
, 1, ,ˆ ˆ ˆ ˆ1 1 (1 )
g g g g
y y y
a b a bsa a
ab ab b ab+
æ öæ ö æ öæ ö¶ - ¶ ¶ - ¶ -D -
= = = =ç ÷ç ÷ ç ÷ç ÷¶ ¶ ¶- - ¶ -è øè ø è ø è ø
 
So 
2 2 2 2 2 2 2 2 2
2 2 4
2 2 2
2 2
2 2 4
2
ˆ(1 ) 1 1 (1 ) 1 (1 ) (1 ) (1 )ˆ( ) ˆ ˆ ˆ(1 ) (1 )(1 ) (1 ) (1 )
ˆ(1 ) 1 (1 ) (1 )(1 ) ˆ ˆ(1 ) (1 )ˆ ˆ ˆ(1 ) (1 ) (1 )
1
ATVar n
n n
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s a b a b b b a a b b
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